Clinical Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2

Summary

A Randomized, Double-blind, Multi-center, Placebo-controlled, Phase III Trial to Evaluate the Efficacy and Safety of DW1026C1 or DW1026C2 Add-on to Metformin in Patients With Type 2 Diabetes Inadequately Controlled With Metformin and Sitagliptin Combination Therapy

Timeline

Start

2022-10-27

Primary completion

2023-12-04

Completion

2024-06-19

Publications

• Lim S, Kim TN, Mok JO, Chung CH, Hwang YC, Cho HC, Won JC, Jeon E, Kang ES, Lee KY, Kim CH, Kwak SH, Park CY, Park KS, Kim SY, Lee JH, Lee SH, Cho DH, Kwon HS, Han KA. Efficacy and Safety of Fixed-Dose Combinations of Sitagliptin and Empagliflozin as Add-On to Metformin in Korean Patients With Type 2 Diabetes: A Randomised, Double-Blind, Multi-Centre, Placebo-Controlled, Phase III Trial. Diabetes Obes Metab. 2026 Jun;28(6):4847-4859. doi: 10.1111/dom.70669. Epub 2026 Mar 26.

Drugs

Indications